300199 Stock Overview
Engages in the development, manufacture, and commercialization of therapeutic peptides API and peptide-based drugs in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 300199 from our risk checks.
Hybio Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥11.58 |
| 52 Week High | CN¥15.97 |
| 52 Week Low | CN¥8.83 |
| Beta | 0.70 |
| 11 Month Change | -3.42% |
| 3 Month Change | 29.10% |
| 1 Year Change | -23.92% |
| 33 Year Change | 34.34% |
| 5 Year Change | 107.16% |
| Change since IPO | -39.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300199 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -7.4% | -0.6% | -2.8% |
| 1Y | -23.9% | -8.7% | 2.0% |
Return vs Industry: 300199 underperformed the CN Pharmaceuticals industry which returned -7.9% over the past year.
Return vs Market: 300199 underperformed the CN Market which returned 3.2% over the past year.
Price Volatility
| 300199 volatility | |
|---|---|
| 300199 Average Weekly Movement | 9.5% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 300199 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300199's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 895 | Yu Pinxiang | www.hybio.com.cn |
Hybio Pharmaceutical Co., Ltd. engages in the development, manufacture, and commercialization of therapeutic peptides API and peptide-based drugs in China and internationally. It offers liraglutide, semaglutide, and exenatide for diabetes; terlipressin, desmopressin, and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix, and atosiban for obstetrics and gynecology; customized peptides; working standards for the peptide APIs and related impurities; peptide CRO; and CDMO services, which include peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory, and dossier support. The company was founded in 1998 and is based in Wuhan, China.
Hybio Pharmaceutical Co., Ltd. Fundamentals Summary
| 300199 fundamental statistics | |
|---|---|
| Market cap | CN¥10.23b |
| Earnings (TTM) | -CN¥368.13m |
| Revenue (TTM) | CN¥405.05m |
25.3x
P/S Ratio-27.8x
P/E RatioIs 300199 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300199 income statement (TTM) | |
|---|---|
| Revenue | CN¥405.05m |
| Cost of Revenue | CN¥263.55m |
| Gross Profit | CN¥141.51m |
| Other Expenses | CN¥509.64m |
| Earnings | -CN¥368.13m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 34.93% |
| Net Profit Margin | -90.88% |
| Debt/Equity Ratio | 253.5% |
How did 300199 perform over the long term?
See historical performance and comparison